Last updated: May 25, 2026
Suppliers for Amlodipine Besylate and Atorvastatin Calcium APIs and Finished Dosage Forms: Who Provides Supply and What to Verify
Executive summary: Amlodipine besylate and atorvastatin calcium are mature, widely sourced molecules. Supplier decisions should be based on (1) whether you need API vs finished dosage forms, (2) regulatory status and FDA inspection history of each site, (3) whether the supplier can support your targeted strengths (including any fixed-dose combinations), and (4) whether you need DMF/CEP-backed materials that match your regulatory filing strategy. Without a specified market (US/EU/ROW), dosage form (tablet vs capsule vs combination), and role (API procurement vs contract manufacturing), a complete supplier list with compliance-grade validation cannot be produced.
What suppliers make amlodipine besylate API and who are the common CMO sources?
Featured snippet answer: The market for amlodipine besylate API is supplied by multiple global API manufacturers and second-source distributors; the procurement path typically routes through (a) API manufacturers with DMFs and (b) CMO/CDMO finished dose manufacturers that buy API and formulate tablets.
API supply verification checklist for amlodipine besylate
- Confirm the supplier’s API is tied to the correct chemical form and salt: amlodipine besylate (not free base).
- Verify regulatory standing for each manufacturing site:
- FDA DMF coverage (if you rely on cross-reference).
- Current good manufacturing practice status via FDA inspection outcomes and import alerts linked to the site.
- Request batch-level chemistry and impurity profile aligned to your specification (including genotoxic impurity controls if applicable to the supplier’s process).
Finished dosage supply checklist for amlodipine tablets
- Confirm the supplier can produce your target strengths and packaging format (bottles vs blister) and can support site-level batch traceability for investigations and quality agreements.
- Ensure the finished dose is manufactured under a validated process for:
- dissolution profile,
- tablet hardness and friability,
- impurity carryover limits from incoming API.
What suppliers make atorvastatin calcium API and who are the leading contract manufacturers?
Featured snippet answer: Atorvastatin calcium is supplied by a global set of API producers and finished-dose manufacturers. Procurement typically depends on whether you need direct API with regulatory documentation or a turnkey tablet/capsule program.
API supply verification checklist for atorvastatin calcium
- Confirm the correct API identity and salt form: atorvastatin calcium.
- Validate the supplier’s impurity strategy:
- control of organic impurities tied to the synthetic route,
- stability-related impurity drift under your proposed packaging conditions.
- Match the API specification to your intended finished-dose specification so you do not have to re-qualify the formulation.
Finished dosage supply checklist for atorvastatin tablets
- Verify supplier capability for the strength ladder (commonly 10/20/40/80 mg tablets, depending on market).
- Confirm dissolution and bioequivalence-relevant parameters for the intended reference product target.
What certifications and regulatory documents should you require from suppliers of amlodipine and atorvastatin?
Featured snippet answer: For both drugs, buyers usually require regulatory traceability via DMF/CEP, site-level GMP evidence, and quality agreements covering change control, deviations, and stability.
Minimum supplier documentation (API)
- DMF letter-of-access or direct DMF reference package (where applicable).
- CoA with impurity-by-impurity reporting aligned to your spec.
- Validation package summaries for critical steps (where required by your quality system).
- Change control commitments (process changes, raw material changes, and analytical method changes).
Minimum supplier documentation (finished dose)
- Written GMP compliance evidence for the finished-dose site(s).
- Batch manufacturing record traceability commitments under QMS audits.
- Stability protocol and results for your proposed shelf life and storage conditions.
Which suppliers support fixed-dose combination tablets (amlodipine + atorvastatin) and what’s the procurement path?
Featured snippet answer: Fixed-dose combination products, where offered in certain markets, are typically manufactured through CDMO/CMO pathways using a controlled formulation and validated co-processing approach. Procurement depends on whether you need an original combination license, a repack, or a generic/comparator product.
Combination procurement risks
- Different label compositions and excipient systems across markets.
- Regulatory strategy: single NDA/ANDA vs separate drug filings can change your supplier qualification requirements.
- Patent status: combination products can inherit separate exclusivity/patent constraints for each active, plus formulation/method-of-use risks in some jurisdictions.
How many suppliers can provide amlodipine besylate and atorvastatin calcium, and how do you manage second-source strategy?
Featured snippet answer: Both actives are widely sourced, so second-source strategies are feasible. The limiting factor is often regulatory documentation alignment, not raw availability.
Second-source strategy that reduces quality/regulatory friction
- Use suppliers that can offer either:
- DMF-backed APIs with aligned impurity profiles, or
- finished-dose manufacturing for your exact target strength/form.
- Pre-qualify two sites per active at minimum, with documented comparability:
- incoming API spec,
- finished-dose dissolution and stability comparability,
- change control terms.
What generic entry risks exist for tablets containing amlodipine besylate or atorvastatin calcium?
Featured snippet answer: For both actives, generic entry risk is generally more about product-specific regulatory and patent landscapes than about molecule-level scarcity. The risk shifts to:
- patent estates for specific dosage forms/strengths,
- process/formulation patents for the chosen manufacturing route,
- data exclusivity and patent protection tied to the specific brand reference product in the target jurisdiction.
Practical risk controls
- Run a strength-by-strength patent screen for your target reference product.
- Ensure your selected supplier’s formulation and manufacturing route are not structurally tied to protected processes or protected impurity specifications.
- For combination products, screen combination-specific formulation and method-of-use patents.
Which manufacturing sites are safest to qualify: what to evaluate in supplier due diligence?
Featured snippet answer: The safest suppliers are those whose sites have stable compliance history, mature documentation systems, and tested change control under a quality agreement.
Due diligence scoring factors
- FDA inspection outcomes for the site (and remediation history).
- Recurrence of OOS/OOT issues and deviation closure performance.
- Ability to support regulatory filings with DMF, CoA traceability, and validated analytical methods.
- Stability data integrity:
- real-time and accelerated stability under your proposed storage conditions,
- method stability and out-of-spec investigation capability.
How does the supplier choice affect CMC timelines for amlodipine and atorvastatin products?
Featured snippet answer: Supplier selection determines CMC cycle time through documentation readiness, analytical method transfer burden, and stability/bridging needs.
CMC timeline drivers
- If supplier API matches your target spec and you can reference DMF data, you reduce method transfer and comparability work.
- If API impurities or physical properties differ (particle size distribution, polymorph-related behavior), you trigger additional formulation work and bridging stability.
Key Takeaways
- Amlodipine besylate and atorvastatin calcium are widely available; supplier selection is primarily a regulatory and quality documentation problem, not a procurement scarcity problem.
- Decide procurement scope early: API supply vs finished dose vs fixed-dose combination.
- Require site-level GMP evidence, DMF/CEP-backed documentation where needed, and quality agreements with robust change control.
- Use second-source qualification based on regulatory documentation alignment and impurity profile comparability to reduce CMC delays.
FAQs
- What should my API specification include for amlodipine besylate suppliers (impurity set, polymorph controls, particle size)?
- How do I qualify an atorvastatin calcium API supplier without redoing my finished-dose dissolution and stability package?
- What quality agreements are non-negotiable when contracting for both API supply and finished-dose manufacturing?
- How do fixed-dose combination supply chains change stability, testing, and regulatory documentation requirements?
- What are the most common supplier-caused failure modes in CMO-manufactured amlodipine or atorvastatin tablets?
References
- Not provided.
